Biokine Therapeutics Awarded FDA Orphan Drug Designation for Mobilization of Stem Cells in Cancer Patients

REHOVOT, Israel, July 24, 2012 /PRNewswire/ –

Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation
from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem
cells from bone marrow into peripheral blood for collection and subsequent transplantation
in patients with hematological cancers. Earlier in 2012, Biokine received FDA approval to
conduct a Phase 2 clinical study for stem cell mobilization in Multiple Myeloma and
Non-Hodgkin’s lymphoma patients utilizing BKT140.

(Logo:
http://photos.prnewswire.com/prnh/20120724/546336 )

Biokine had previously completed a Phase 1/2 clinical study at several prestigious
medical centers in Israel which indicated both the drug’s safety and efficacy and its
ability to shorten the number of treatment days and subsequent aphaeresis procedures.

Dr. Laurence Shaw, the Chairman of Biokine’s board of directors, said today that
“BKT140 is uniquely positioned to enter the fast evolving market for stem cell
mobilization for hematological malignancies. In these cost constrained times, BKT140,
which allows for a reduction in the cost of patient care, is a highly competitive drug. In
addition, in both preclinical and clinical studies BKT140 had shown that by targeting the
chemokine receptor CXCR4, BKT140 also appears to have the potential to treat malignancies
involving this key receptor.”

Biokine Therapeutics Ltd. is an emerging biopharmaceutical company that is developing
novel therapeutic agents for use in stem cell cancer therapeutics, cancer, and in the
treatment of autoimmune and inflammatory diseases. The Company is based in the Weizmann
Science Park in Rehovot, Israel. Biokine was founded by its Chief Scientific Officer and
Chief Executive Officer, Professor Amnon Peled, a leading expert and researcher in the
CXCR4 scientific community. The Company has a proprietary Chemohit drug discovery
technology and has several preclinical compounds in development.

        Contact:
        Dr. Laurence Shaw
        +972-8-9301015
        info@biokine.com

http://www.biokine.com

    Photo: 

http://photos.prnewswire.com/prnh/20120724/546336

SOURCE Biokine Therapeutics Ltd.